Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 314
Selected: 0
NCT IDTitle
NCT06744647Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT05259085Study of ALXN2050 in Participants With Hepatic Impairment
NCT00438789The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
NCT06830798Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT00375609Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
NCT00040144Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
NCT03310021A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
NCT05556096Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT04802083COVID-19 Soliris Expanded Access Protocol
NCT00088179Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
NCT04980248Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
NCT04526197Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
NCT01994382Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
NCT05319912A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT02618512A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
NCT06374264Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
NCT02193867Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
NCT01633489Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT05047523Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
NCT02926872Screening for Lysosomal Acid Lipase Deficiency
NCT06079281Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT00751231A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
NCT06607627PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
NCT02090179Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging
NCT04021082CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
NCT01192425Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
NCT00380159Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
NCT05368038ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
NCT05884060Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
NCT03418389Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia
NCT01192399Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT05982938Danicopan Early Access Program
NCT05565092Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease
NCT03406507A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
NCT02245867Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
NCT07337395Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
NCT05109390A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
NCT05047484A Study of Multiple Doses of ALXN2050 in Healthy Adults
NCT07413250Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
NCT05097989Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT02207725A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
NCT05307978Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants
NCT01883544Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects
NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT03920293Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
NCT04743804Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
NCT00935883Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
NCT02376751An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency
NCT01403389A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant